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Abstract: 3,4-Methylenedioxymethamphetamine (MDMA) is an illicit psychoactive drug 
with cardiovascular effects that have not been fully described. In the current study, we 
observed the effects of acute MDMA on rabbit left ventricular function. We also observed 
the  effects  of  MDMA  on  nuclear  factor-kappa  B  (NF-B)  activity  in  cultured  rat 
ventricular myocytes (H9c2). In the rabbit, MDMA (2 mg/kg) alone caused a significant 
increase  in  heart  rate  and  a  significant  decrease  in  the  duration  of  the  cardiac  cycle. 
Inhibition of nitric oxide synthase (NOS) by pretreatment with L-NAME (10 mg/kg) alone 
caused significant dysfunction in heart rate, systolic pressure, diastolic pressure, duration 
of relaxation, duration of cardiac cycle, and mean left ventricular pressure. Pretreatment 
with  L-NAME  followed  by  treatment  with  MDMA  caused  significant  dysfunction  in 
additional  parameters  that  were  not  abnormal  upon  exposure  to  either  compound  in 
isolation:  duration  of  contraction,  inotropy,  and  pulse  pressure.  Exposure  to  1.0  mM 
MDMA for 6 h or 2.0 M MDMA for 12 h caused increased nuclear localization of NF-B 
in cultured H9c2 cells. The current results suggest that MDMA is acutely detrimental to 
heart function and that an intact cardiovascular NOS system is important to help mitigate 
early sequelae in some functional parameters. The delayed timing of NF-B activation 
suggests that this factor may be relevant to MDMA induced cardiomyopathy of later onset. 
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1. Introduction  
3,4-Methylenedioxymethamphetamine (MDMA) is a widely used recreational drug among teens 
and  young  adults.  This  substance  has  molecular  similarities  to  amphetamine  and  mescaline  [1]. 
Unsurprisingly,  users  of  MDMA  report  subjective  effects  attributable  to  both  compounds  [1]. 
Although the physiological impact of this drug has yet to be fully characterized, and exact mechanistic 
details are still being elucidated, the growing body of evidence continues to support the theory that 
MDMA abuse is detrimental to the cardiovascular system [1–10]. 
In humans, MDMA use can cause abnormal increases in heart rate, mean arterial pressure, and 
myocardial wall stress [2]. In rats, binge pattern intravenous administration of MDMA (9 mg/kg) 
induces profound and progressive bradycardia with accompanying hypotension [3]. There is evidence 
that MDMA may directly affect heart function by prolonging Purkinje fiber action potential duration 
[7]. Other evidence suggests that systemic effects in the form of autonomic dysregulation may be more 
important in the rhythmic and pressor abnormalities seen with MDMA abuse [4,10]. This may involve 
increased net release of norepinephrine and alpha-adrenergic receptor interaction [1,4,5,9]. In addition, 
abnormally elevated intracellular calcium, as observed in our own previous experiments with MDMA, 
may lead to further complications including myocardial hypertrophy, fibrosis, and apoptosis [8,11,12].  
The direct  mechanism(s)  by which MDMA  causes adverse cardiovascular effects  is  still under 
investigation. In cardiac myocytes, one important transcription factor activated by MDMA is nuclear 
factor-kappa  B  (NF-B)  [11].  NF-B  is  ubiquitously  found  in  a  wide  variety  of  cell  types  as  a 
heterodimer consisting of p50 and p65 subunits [13–16]. Under normal conditions, NF-B is localized 
mainly in the cytoplasm where it is inhibited by the I-kappa B () family of regulatory proteins [17]. 
Activation  occurs  when  B  becomes  phosphorylated,  ubiquitinated,  and  subsequently  degraded 
allowing  for  translocation  into  the  nucleus  where  NF-B  binds  to  B-response  elements  in  the 
promoter/enhancer regions of various genes [13,18–23]. This process upregulates the expression of 
various  downstream  inflammatory  factors  including  cytokines,  chemotactic  proteins,  and  cellular 
adhesion molecules [23]. There are several well known inducers of NF-B including interleukin-1 
(IL-1,  interleukin-6  (IL-6),  interleukin-8  (IL-8),  tumor  necrosis  factor-  (TNF-), 
lipopolysaccharide  (LPS),  physical  trauma,  ionizing  radiation,  and  free  radicals  [24–28].  Previous 
studies in our laboratory indicate that illicit drugs such as cocaine can also activate this transcription 
factor [11,29].
 
In the heart, NF-B activation is closely associated with pro-inflammatory as well as anti-apoptotic 
conditions.  Rat  cardiac  myocytes  in  culture  exposed  to  an  oxidizing  environment,  such  as  
co-incubation  with  hydrogen  peroxide,  show  an  increased  NF-B  activity  [30].  Myocardial 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) gene 
expression are effectively reduced when NF-B is inhibited [31,32]. These cell surface proteins are 
important in mediating inflammatory cell recruitment and infiltration by acting as counter-receptors for 
circulating monocyte and lymphocyte integrins [32]. The anti-apoptotic nature of NF-B has been 
demonstrated in primary cultures of rat ventricular myocytes. In these cells, TNF- induced apoptosis 
is significantly enhanced by NF-B inhibition [33]. 
Earlier research reveals important information concerning the effects of MDMA on redox balance 
within the cell,  a  critical  aspect in  NF-B regulation. MDMA has been shown to simultaneously Int. J. Mol. Sci. 2010, 11                       
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increase reactive oxygen species (ROS) production and deplete reduced glutathione levels in hepatic 
stellate  cells  [34].  MDMA  also  increases  hydroxyl  radical  formation  in  the  rat  brain  [35]. 
Theoretically, the oxidative stress created by MDMA in these studies can promote NF-B activation, 
modulate downstream genetic expression, and induce an inflammatory response. Supporting evidence 
exists in rats given binge-pattern administration of MDMA over the course of several weeks [3,36]. 
These animals show histological signs of increased lymphocyte infiltration and inflammatory damage 
to the myocardium [3]. They also display significantly elevated nitrotyrosine content of proteins (an 
index of ROS activity) isolated from the left ventricle [36]. 
We have reported that NF-B is activated by MDMA in a dose-dependent manner [11]. By way of 
genetic array technology, we have also observed that several NF-B dependent genes are upregulated 
at the transcriptional level. Some of these genes, such as PCNA, Cox-2, and VCAM-1 have been 
implicated  in  cardiac  disease  states  such  as  heart  failure,  hyperplasia,  fibrosis  and  inflammation 
[32,37,38].  Others,  such  as  Gadd45  and  RAD23A,  are  involved  with  survival  and  compensatory 
responses [39,40]. While genes, such as inducible nitric oxide synthase (iNOS) and brain natriuretic 
peptide (BNP) are upregulated in heart failure, but were not significantly modulated in response to 
MDMA  under  our  conditions.  It  is  possible  that  iNOS  and  BNP  were  affected  at  earlier  time  
points [41,42]. 
iNOS is an important signaling molecule in the cardiovascular system and is under NF-B control 
[41]. The metabolic end product of the enzyme - nitric oxide (NO) is a well known vasodilator and 
helps  to  regulate  blood  pressure  [43–45].  In the compromised endothelium, as  commonly  seen  in 
atherosclerosis, NO output is significantly diminished [46,47]. Atherosclerosis has aberrant functional 
consequences  for  the  heart  such  as  increased  vasoconstriction  and  elevations  in  heart  rate  and 
contractility (inotropy) that may be exacerbated by MDMA use. 
The full scope of MDMA induced effects on the cardiovascular system and the extent of NF-B 
involvement remains incompletely characterized. Therefore, the purpose of the current study was to 
observe the cardiac functional response to acute MDMA administration in the intact rabbit and to 
further characterize molecular events in cultured ventricular myocytes as a result of direct MDMA 
exposure.  We  also  observed  the  effects  of  MDMA  on  nitric  oxide  synthase  inhibition  in  the 
cardiovascular system. 
2. Materials and Methods 
2.1. In Vivo Experiments 
Sixteen adult New Zealand White (NZW) rabbits (Oryctolagus cuniculus) were randomly divided 
into  3  treatment  groups:  Placebo  (n  =  5),  MDMA  (n  =  7),  and  L-NAME  +  MDMA  (n  =  4).  A  
Digi-Med Heart Performance Analyzer- model 410 (Micro-Med; Tustin, CA) was used to measure 
left  ventricular  systolic  pressure  (MaxP),  diastolic  pressure  (EDP),  inotropy  (dP/dt),  lusitropy 
(NdP/dt), duration of contraction (DCON), duration of 1/2 relaxation (1/2R), and heart rate (HR). 
From  these  parameters,  three  additional  parameters  were  calculated:  duration  of  cardiac  cycle 
(CCycle),  mean  ventricular  pressure  (MeanP),  and  pulse  pressure  (PulseP).  The  analyzer  was 
connected to a Millar model SPR-524 catheter (Millar Instruments, Inc.) which contains a specialized Int. J. Mol. Sci. 2010, 11                       
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sensor  tip  designed  for  transducing  mechanical  signals  directly  from  within  the  left  ventricular 
chamber into electrical signals that can be interpreted by the analyzer and recorded by the computer. 
Animals were placed under a surgical plane of anesthesia by administering ketamine (40 mg/kg) 
and xylazine (5 mg/kg) intramuscularly. A 2 cm longitudinal mid-line incision was made parallel to 
the trachea. The left common carotid artery was carefully isolated from the surrounding tissues and a 
Millar catheter gently inserted into the left ventricle. A 24 G ½ inch catheter was inserted into the 
marginal ear vein of the rabbit for the injection of all drugs and solutions. Animals in the placebo 
group  were  given  0.9%  sterile  isotonic  saline  intravenously  (IV).  Animals  in  the  MDMA  group 
received 2 mg/kg MDMA IV bolus. Animals in the L-NAME + MDMA group were pretreated with 
10 mg/kg L-NAME (non-specific NOS inhibitor) 10 min before 2 mg/kg MDMA was injected, IV. 
Left ventricular functional data was recorded every 10 s by the computer during the entire experiment. 
After data collection, the animal was euthanized and the heart was carefully removed and weighed on 
an analytical balance. The left ventricle was separated from all other tissue, snap-frozen with liquid 
nitrogen,  and  stored  at  −80  ° C  until  analysis.  All  functional  data  were  normalized  to  
baseline/pre-injection  parameters  and  statistically  analyzed  as  ratiometric  units  using  single-factor 
ANOVA for each time point. The functional effects of L-NAME alone relative to pre-injection were 
analyzed via paired t-test. 
2.2. In Vitro Experiments 
2.2.1. Reactive Oxygen Species Assay 
These experiments were designed to measure the effects of MDMA on reactive oxygen species 
(ROS) generation in cultured cardiac myocytes. H9c2 cells (Rattus norvegicus) were grown to 85–90% 
confluency in T-75 flasks at 37 ° C and 5% atmospheric CO2 (incubator controlled). Culture media 
consisted  of  15  mL  Dulbecco’s  Modified  Eagle’s  Medium™  containing  10%  fetal  bovine  serum 
(FBS). Cells and media were purchased from American Type Culture Collection (ATCC; Manassas, 
VA, USA). Cell manipulations were carried out under a tissue culture hood using aseptic technique. 
The  green  fluorescent  indicator  2’,7’-dichlorofluorescin  diacetate  (Molecular  Probes)  was  used  to 
measure the presence of MDMA induced ROS generation. On day 1, with the aid of a hemacytometer, 
approximately 150,000 H9c2 cells (approximately 1.05 ×  10
5 cells/cm
2) were plated onto a sterile 
multi-well culture plate (Corning). The cells were then returned to the incubator for 24 hours. 
On day 2, the overlying media was removed and discarded. The cells were washed with 1 mL of 
Hank’s Media (ATCC) in order to remove residual cell culture media which contained a red coloring 
that might interfere with the indicator. Afterward, 1 mL of fresh Hank’s Media was placed in each 
well. 2’,7’-dichlorofluorescin diacetate was dissolved in dimethyl sulfoxide (DMSO) (Sigma). To load 
the cells, 1 mL of the 5% indicator solution was added to each well and the culture plate was gently 
swirled for 1 min. The culture plate was then wrapped in aluminum foil and returned to the incubator 
for 30 min. 
Following the loading period, the cells were washed twice with 1 mL of Hank’s Media. Next, 2 mL 
of fresh Hank's Media was placed into each well and the plate was returned to the incubator for 30 min 
prior  to  drug  administration.  The  following  concentrations  of  MDMA  were  tested:  1  ×  10
−4  M,  Int. J. Mol. Sci. 2010, 11                       
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1 ×  10
−3 M, and 1 ×  10
−2 M. The drug was dissolved in Hank's Media and 2 mL of each concentration 
was gently added to the appropriate wells. Each well served as its own 0 M control. The cells were 
imaged using a Zeiss model 510 LSM confocal microscope (Carl Zeiss) equipped with a variable 
wavelength argon laser, epifluorescent filters, and a digital camera. Cells generating ROS exhibited a 
quantifiable  green  fluorescence.  Images  were captured 2  and 5 min  after drug  exposure and then 
analyzed by the program Metamorph (Universal Imaging) for densitometry. The results were exported 
to Excel (Microsoft) and statistically analyzed using paired t-test. 
2.2.2. ELISA for NF-B 
These  experiments  were  designed  to  determine  the  effect  of  MDMA  on  the  degree  of  NF-B 
activation  in  cultured  cardiac  myocytes.  H9c2  cells  were  grown  and  maintained  as  previously 
described in our ROS experiments. On day 1 of the experiment, approximately 1 ×  10
6 cells were 
plated onto each well of a sterile 6-well culture plate (approximately 1.05 ×  10
5 cells/cm
2) and returned 
to the incubator for 24 hours. On day 2, the cells were stimulated with MDMA or placebo (culture 
media). Two concentrations of MDMA were used: 1.0 mM or 2.0 M. To stimulate the cells, the drug 
was dissolved in an appropriate volume of cell culture media and 5 mL of total solution added to each 
well. An equal volume of cell culture media (without drug) was added to cells that served as our paired 
controls (0 mM MDMA). The cells were then returned to the incubator for either 3, 6, or 12 h. These 
concentrations and exposure times were specifically chosen because of evidence in human subjects 
suggesting that peak MDMA plasma levels occur between 2–4 h after drug administration [48]. Each 
time point and drug concentration was tested independently in separate experiments. 
At  the  end  of  the  drug  exposure  period,  nuclear  extracts  were  obtained  per  manufacturer 
instructions using an extraction kit (AY2002) from Panomics (Fremont, CA). Briefly, the cells were 
washed twice with 10 mL of isotonic phosphate buffered saline (PBS), pH 7.4. Cells were lysed using 
a lysis buffer (1 mL solution of 10 mM HEPES, 10 mM KCl, 10 mM EDTA; 10 L of 100 mM DTT; 
10 L protease inhibitor cocktail; 40 L of 10% IGEPAL) for 10 min. The cells in each well were then 
scraped and transferred to a separate 1.5 mL tube and centrifuged at 14,000 ×  g for 3 min at 4 °C . The 
pellets were retained and placed on ice. 
A separation buffer (147 L solution of 20 mM HEPES, 0.4 M NaCl, 1 mM EDTA, 50% glycerol; 
1.5 L protease inhibitor cocktail; 1.5 L of 100 mM DTT) was used to isolate nuclear proteins. The 
pellets were resuspended in  the separation buffer and gently agitated on ice  for 2 h. The nuclear 
extracts  were  stored  at  −80  ° C  in  sterile  nuclease-free  microcentrifuge  tubes  until  analysis.  A 
quantitative assay (Bradford) was used to determine the total protein concentration of each sample. 
To measure the presence of activated NF-B in the nuclear extracts, a modified ELISA based kit 
(EK1010) from Panomics (Fremont, CA) was used. A specialized 96 well microplate pre-coated with 
NF-B binding consensus oligonucleotide was incubated with 2.0 g of total nuclear extract. Primary 
antibody to the p50 subunit of NF-B was added to each well at a dilution of 1:100. Conjugated 
secondary antibody was added to each well at a dilution of 1:1000. Colorimetric substrate was added 
and the reaction allowed to incubate at room temperature for 15 min. The plate was then analyzed at 
A450 nm using a FluoStar™ spectrophotometric microplate reader (BMG Labtech, Inc. Durham, NC). 
The results were exported to Excel (Microsoft) and statistically analyzed using the paired t-test. Int. J. Mol. Sci. 2010, 11                       
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In order to test for NF-B activity in left ventricular heart tissues of acutely treated rabbits, another 
set of experiments was performed. Nuclear extracts were obtained per manufacturer instructions using 
an extraction kit (AY2002) from Panomics (Fremont, CA). A quantitative assay (Bradford) was used 
to determine the total protein concentration of each sample. 
To measure the presence of activated NF-B in the nuclear extracts, a modified ELISA based kit 
(P/N 12490) from Panomics (Fremont, CA) was used. A specialized 96 well microplate pre-coated 
with streptavidin was incubated with a mixture containing 10.0 L binding buffer, 2.5 L NF-B 
specific biotinylated oligonucleotide probe, and 1.0 g of total nuclear extract. Primary antibody to the 
p50 subunit of NF-B was added to each well at a dilution of 1:200. Conjugated secondary antibody 
was added to each well at a dilution of 1:200. Colorimetric substrate was added and the reaction was 
allowed  to  incubate  at  room  temperature  for  15  min.  The  plate  was  then  analyzed  as  previously 
described.  The  results  were  exported  to  Excel  (Microsoft)  and  statistically  analyzed  using  the  
two-sample t-test. 
3. Results 
3.1. In Vivo Experiments 
Analysis of left ventricular mechanical function revealed that MDMA alone significantly increased 
heart rate 5 min after injection (Figure 1) and decreased the duration of the cardiac cycle at the 15 min 
time point (Figure 2). The elevation in heart rate persisted throughout the remainder of post-injection 
monitoring. No significant changes in any of the other functional parameters were observed in the 
MDMA treated group relative to the Placebo group. 
In the group of animals pretreated with L-NAME and then given MDMA (L-NAME + MDMA), 
heart rate (Figure 1) was significantly decreased while systolic and diastolic pressures, duration of 
contraction, duration of relaxation, duration of cardiac cycle, mean pressure, and pulse pressure were 
all significantly elevated from baseline (Figures 2–9). dP/dt showed a significant increase relative to 
the MDMA group at the 1 min mark. 
L-NAME alone significantly decreased heart rate, but elevated systolic pressure, diastolic pressure, 
duration of relaxation, duration of cardiac cycle, and mean pressure (Figure 10). DCON, dP/dt, and 
PulseP were not significantly affected by L-NAME alone. However, after the addition of MDMA, 
these parameters were significantly increased. 
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Figure 1.  Normalized heart  rate (mean ±  SD).  Placebo  group (n  = 5)  received sterile 
isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA. L-NAME + MDMA 
group (n = 4) received 10 mg/kg L-NAME for 10 min followed by 2 mg/kg MDMA.  
* p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA. 
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Figure 2. Normalized systolic pressure (mean ±  SD). Placebo group (n = 5) received sterile 
isotonic  saline.  MDMA  group  (n  =  7)  received  2  mg/kg  MDMA.  
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed 
by 2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA. 
Systolic Pressure
^
*
^
* ^
*
0
0.5
1
1.5
2
2.5
3
3.5
Placebo MDMA L-NAME+MDMA
N
o
r
m
a
l
i
z
e
d
 
m
m
 
H
g
 
 
 
 
 
 
 
 
 
.
1 min
5 min
15 min
 
 Int. J. Mol. Sci. 2010, 11                       
 
4850 
Figure 3. Normalized diastolic pressure (mean ±  SD). Placebo group (n = 5) received 
sterile  isotonic  saline.  MDMA  group  (n  =  7)  received  2  mg/kg  MDMA.  
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed 
by 2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA. 
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Figure 4. Normalized duration of contraction (mean ±  SD). Placebo group (n = 5) received 
sterile  isotonic  saline.  MDMA  group  (n  =  7)  received  2  mg/kg  MDMA.  
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed 
by 2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA. 
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Figure 5. Normalized duration of relaxation (mean ±  SD). Placebo group (n = 5) received 
sterile  isotonic  saline.  MDMA  group  (n  =  7)  received  2  mg/kg  MDMA.  
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed 
by 2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA. 
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Figure  6.  Normalized  duration  of  cardiac  cycle  (mean  ±   SD).  Placebo  group  (n  =  5) 
received  sterile  isotonic  saline.  MDMA  group  (n  =  7)  received  2  mg/kg  MDMA.  
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 min followed by 
2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA. 
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Figure 7. Normalized mean pressure (mean ±  SD). Placebo group (n = 5) received sterile 
isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA. L-NAME + MDMA 
group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed by 2 mg/kg MDMA.  
* p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA. 
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Figure 8. Normalized pulse pressure (mean ±  SD). Placebo group (n = 5) received sterile 
isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA. L-NAME + MDMA 
group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed by 2 mg/kg MDMA.  
* p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA. 
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Figure 9. Normalized dP/dt (mean ±  SD). Placebo group (n = 5) received sterile isotonic 
saline. MDMA group (n = 7) received 2 mg/kg MDMA. L-NAME + MDMA group (n = 4) 
received 10 mg/kg L-NAME for 10 minutes followed by 2 mg/kg MDMA. ^ p < 0.05 
compared to MDMA. 
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Figure  10.  Effects  of  L-NAME  on  cardiac  functional  parameters  (mean  ±   SD).  
L-NAME + MDMA group (n = 4). Pre-injection parameters were record for 15 minutes. 
Post-injection of 10 mg/kg L-NAME was recorded for 10 minutes. * p < 0.05 compared to 
pre-injection. 
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3.2. In Vitro Experiments 
3.2.1. Reactive Oxygen Species Assay 
Using cultured H9c2 cells, we observed a significant increase in ROS generation in response to 
MDMA  exposure. ROS  generation was  significantly  elevated  relative to  0 M  control  5 min  after 
exposure to 1 ×  10
−2 M MDMA (Figure 11). 
Figure 11. ROS assay signal intensity at 5 min (mean ±  SD). Each well served as its own 
control (n = 3). * p < 0.05 compared to Control Signal. 
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3.2.2. ELISA for NF-B 
We observed  a significant  increase in nuclear  localization of NF-B in  H9c2  cells  exposed to 
1.0 mM MDMA at the 6 h time point (Figure 12). Measurements taken at the 3 h and 12 h time points 
for cells exposed to 1 mM MDMA were not significantly different from their paired controls. We also 
observed significant nuclear localization of NF-B with the 2.0 M dose, however this occurred at the 
12 h time point (Figure 13). In addition, we did not observe a significant difference in NF-B activity 
between  the  placebo  and  MDMA  groups  in  myocardial  tissue  specimens  from  our  functional 
experiments (data not shown). 
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Figure 12. ELISA for NF-B nuclear localization (mean ±  SD). Either 0 mM MDMA 
(media  only)  (n  =  3)  or  1  mM  MDMA  (n  =  3)  was  used  at  each  time  point.  Each 
experiment  was  performed  independently.  A  kit-provided  assay-level  positive  control  
(+Control) of nuclear extracts prepared from IL-1 treated HeLa cells was included during 
the plate run. * p < 0.05. 
 
Figure 13. ELISA for NF-B nuclear localization (mean ±  SD). Either 0 M MDMA 
(media  only)  (n  =  3)  or  2  M  MDMA  (n  =  3)  was  used  at  each  time  point.  Each 
experiment  was  performed  independently.  A  kit-provided  assay-level  positive  control  
(+Control) of nuclear extracts prepared from IL-1 treated HeLa cells was included during 
the plate run. * p < 0.05. 
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4. Discussion 
4.1. Effects of MDMA 
In  this  study  we  further  characterize  the  effects  of  MDMA  on  the  cardiovascular  system.  The 
widespread abuse of MDMA, along with the possibility of direct and indirect effects contributing to 
both  acute  and  long-term  sequelae,  makes  this  drug  particularly  important  in  terms  of  potential 
cardiotoxicity. We show, in the intact rabbit, that MDMA can cause acute functional abnormalities of 
the left ventricle and that NOS signaling may be an important protective response. We also show, in 
cultured  cardiac  myocytes,  that  MDMA  has  the  potential  to  activate  NF-B,  a  key  molecular 
transcription factor associated with myocardial pathology. The current findings support earlier reports 
that implicate MDMA in augmenting both sympathetic responses and NF-B activity [1–5,9,10]. 
Compared to placebo, MDMA alone caused a 21% increase in heart rate 15 min after injection and 
significantly decreased the duration of the cardiac cycle at the same time point (17%). Due to the early 
onset  of  the  cardiovascular  responses,  and  the  fact  that  NF-B  activation  in  our  cultured  cardiac 
myocytes was not observed at or before the 3 h time point with either MDMA dose, these responses 
may  not  be  the  result  of  interaction  with  the  myocardial  NF-B  pathway.  Two  possibilities  may 
explain  these  results.  The  injected  MDMA  may  have  directly  and  rapidly  affected  cardiovascular 
calcium homeostasis in blood vessels and led to the slight increase in systolic and diastolic pressures. 
This  is  unlikely,  however,  because  the  changes  in  pressures  were  slight  and  non-significant.  It  is 
possible that MDMA may have stimulated systemic sympathetic activity by causing a net increase in 
epinephrine and norepinephrine release from central stores and/or peripheral nerve endings. This idea 
is supported by the fact that there was a significant increase in heart rate 5 and 15 min after MDMA 
injection and suggests a possible direct effect of MDMA on the sinoatrial node of the heart or indirect 
stimulation via catecholamines. 
Previously, we have demonstrated that MDMA causes a significant increase in intracellular calcium 
in cultured H9c2 cells within a few minutes of drug administration [11]. Elevated calcium levels may 
affect intracellular signaling pathways leading to diverse pathological responses including fibrosis and 
hypertrophy.  Disruptions  in  calcium  homeostasis  may  also  alter  myocardial  excitability  and 
contractility,  which  may  induce  ventricular  arrhythmia  and  other  more  immediate  functional 
abnormalities such as the increased heart rate and decreased cardiac cycle duration observed in the 
present study. An increase in heart rate associated with a decrease in the duration of the cardiac cycle 
may  suggest  that  filling  and  ejection  of  blood  in  the  heart  exposed  to  MDMA  may  be  acutely 
compromised. 
In cultured H9c2 heart cells, a significant increase in ROS generation was observed 5 min after  
1 ×  10
−2 M MDMA exposure. Although we exposed the H9c2 heart cells to MDMA acutely and 
measured ROS generation 5 min later, the half-life of MDMA has been reported to be approximately  
9 ±  2.2 h [49]. In addition, there is evidence that MDMA metabolites adversely affect cardiac myocyte 
redox balance [6]. MDMA is metabolized into toxic metabolites including HMMA, MDA, and HMA, 
and may lead to the formation of peroxinitrite, all of which may prolong and exacerbate the deleterious 
effects of the drug [50–52]. In vivo and in vitro studies provide evidence supporting the role of both 
excessive monoamine release and  oxidative stress  in  cardiovascular  conditions  (such as  ischemia-Int. J. Mol. Sci. 2010, 11                       
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reperfusion injury, hypertension, catecholamine-induced cardiomyopathy, and heart failure) that lead 
to cardiovascular dysfunction [53–55]. In addition to generation of ROS, 1.0 mM of MDMA also 
significantly increased the activity of NF-B in H9c2 heart cells in culture after 6 h of exposure. After 
12  h  of  exposure,  2.0  M  MDMA  significantly  enhanced  NF-B  activity.  This  redox  sensitive 
transcription  factor  is  known  to  upregulate  the  expression  of  genes  associated  with  myocardial 
inflammation, hypertrophy, and fibrotic scar formation. 
Preliminary evidence from our lab indicates that NF-B is not significantly activated in H9c2 cells 
exposed to MDMA for less than 3 h (data not shown). It is possible that under the current experimental 
conditions 3 h is not sufficient time for significant nuclear accumulation of this transcription factor. 
Based upon our previous investigation [11], a biphasic response to 1.0 mM MDMA is suggested since 
sometime after 6 h, nuclear presence of NF-B becomes significantly degraded, but then reappears at 
the 24 h time point according to our genetic reporter study. It is uncertain why this drug is associated 
with a temporal response with regard to NF-B.  It is possible that some metabolic by-product  of 
MDMA may be participating later in the NF-B response and/or cellular adaptation is occurring in 
response to the persistent presence of metabolites over extended periods of time. 
Significant  NF-B  activity  was  absent  in  the  myocardial  tissue  samples  from  our  functional 
experiments. Since the animals were exposed to MDMA for only 15 min prior to euthanasia and tissue 
harvesting, the lack of NF-B activity is in agreement with our cell culture findings within the same 
timeframe. Therefore, it is unlikely that any of the acute functional responses induced by MDMA are 
due to the activation of myocardial NF-B and the consequent expression of downstream dependent 
genes such as inflammatory cytokines and adhesion molecules. It is more likely that other tissues, such 
as the vasculature and/or sympathetic peripheral nerve endings may be responsive to this drug within 
the tested timeframe and may contribute to the abnormal functional findings in the left ventricle by 
increasing  peripheral  resistance.  Another  possibility  is  that  MDMA  induced  ROS  generation,  as 
observed in the current study, and abnormal intracellular Ca
2+ elevation, as observed in our previous 
study  [11],  presents  a  more  immediate  threat  to  normal  cardiac  function  since  these  events  were 
precipitated rapidly after drug exposure. 
4.2. MDMA and L-NAME 
Since MDMA activates NF-B, we predicted that downstream dependent genes such as inducible 
nitric  oxide  synthase  (iNOS)  would  be  upregulated  as  a  result  of  MDMA  exposure.  iNOS  is  a 
cardioprotective enzyme closely associated with compensatory actions in the heart during ischemic 
preconditioning and inflammatory cytokine exposure [56,57]. It is possible that MDMA stresses the 
heart and causes the myocardium to respond in an adaptive manner by increasing the synthesis of this 
enzyme. In the current study, we performed an independent series of in vitro experiments in which we 
again exposed H9c2 heart cells in culture to 2.0 M and 1.0 mM concentrations of MDMA. We did 
not observe a significant change in the expression of iNOS at the protein level. Since iNOS expression 
in cardiac myocytes is NF-B dependent, it is still possible that a certain degree of iNOS expression 
occurred below the threshold for detection, or at time points earlier than we examined. 
The importance of an intact nitric oxide signaling system in reducing the adverse functional effects 
of MDMA is readily apparent in our functional experiments. L-NAME is a well characterized inhibitor Int. J. Mol. Sci. 2010, 11                       
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of the major NOS isoforms [58,59]. In the rat, this compound induces a dose-dependent increase in 
heart  rate  and  mean  arterial  pressure  [58].  L-NAME  also  decreases  blood  flow  by  increasing 
vasoconstriction in several vascular beds including those associated with the kidneys, mesenteries, and 
hindquarters  [60].  Endothelial  NOS  (eNOS)  is  particularly  important  to  normal  cardiovascular 
function. In mice, decreased expression of eNOS reduces vasorelaxation capacity and increases arterial 
pressure [61]. 
In our experiments, injection of L-NAME alone caused a significant increase in heart rate, left 
ventricular systolic and diastolic pressures, the duration of left ventricular relaxation and the duration 
of the cardiac cycle. When the animal was given MDMA alone, heart rate increased and the duration 
of the cardiac cycle decreased. These results are consistent with what was expected since the duration 
of the cardiac cycle is inversely proportional to the heart rate. In the presence of L-NAME, MDMA 
decreased heart rate and increased the duration of the cardiac cycle. These results may suggest that one 
mechanism used by MDMA to alter heart function is via the nitric oxide synthase pathway. Nitric 
oxide has been shown to play a role in the modulation of sympathetic nerve activity and baroreflex 
sensitivity [62]. For instance, if MDMA and L-NAME are both sympathomimetic synergists, then the 
increased systolic pressure induced by L-NAME may be enhanced by the addition of MDMA. The 
consequent  decrease  in  heart  rate  may  be  exclusively  due  to  the  effects  of  L-NAME  or  the 
compensatory baroreceptor reflexes of the intact cardiovascular system responding to the slight change 
in pressure. It is therefore not possible, in this model, to separate the reflex component of the response 
to these drugs. 
The use of MDMA may have important implications for individuals with a compromised vascular 
endothelium, as seen in atherosclerosis. Endothelial cells are an important source of nitric oxide which 
helps to maintain normal blood pressure by regulating vascular diameters and peripheral resistance. 
Therefore, users of MDMA with extensive atherosclerotic lesions may be at increased risk for the 
development of acute rhythmic abnormalities and subsequent heart failure. 
5. Conclusions 
This study provides evidence that MDMA is acutely detrimental to normal heart function. The 
current evidence also suggests that an intact cardiovascular NOS system exerts a partially protective 
response to the drug in some, but not all, functional parameters. It is likely that MDMA induced 
autonomic dysregulation contributes to the functional abnormalities we observed and that these effects 
are characteristic of the immediate/early consequences of abuse. In addition, MDMA may be toxic to 
the myocardium due to its ability to increase ROS generation and activate NF-B. However, since the 
NF-B response was significantly elevated in vitro only after several hours past initial exposure and 
not elevated in vivo during the timeframe of our functional studies, the acute detrimental effects of 
MDMA on heart function may not be related to myocardial activation of this transcription factor. 
Nevertheless, it remains possible that sequelae of latter onset may be caused by NF-B activation and 
the expression of genes under its control. Further investigations involving MDMA and the effects of 
various patterns and durations of drug exposure will yield important additional information as to the 
true nature of this substance and its impact on the cardiovascular system. 
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